Michael Wang, MD, discusses the role of BTK inhibitors as treatment of patients with mantle cell lymphoma ahead of his presentation at the 2020 SOHO Annual Meeting.
Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the role of BTK inhibitors as treatment of patients with mantle cell lymphoma (MCL) ahead of his presentation at the 2020 SOHO Annual Meeting.
Wang believes the overall survival of patients with MCL will continue to be prolonged. The first approved targeted treatment option in MCL was bortezomib (Velcade), which presented with an objective response rate (ORR) of 32%. Lenalidomide (Revlimid) was the second drug to be approved a few years later in 2013, which had an ORR of 25%.
Ibrutinib (Imbruvica) was later approved for the treatment of patients with MCL. Wang says he had the honor of leading the clinical trial that led to this agent’s approval, which had an ORR of 68% and a complete response rate of 20%. Several years later, acalabrutinib (Calquence) was also approved, which had great survival outcomes as well. Zanubrutinib (Brukinsa) was approved by the FDA, marking the third BTK inhibitor approved for the treatment of MCL.
Darolutamide Becomes Routine Doublet and Triplet Option in Hormone-Sensitive Prostate Cancer
May 6th 2024Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.
Read More
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More
UGN-101 Shows Promise for Upper Tract Urothelial Cancer Durability
May 5th 2024Maintenance UGN-101 therapy demonstrated good durability of response in initial responders with low-grade upper tract urothelial cancer, as evidenced by a low rate of disease progression in a multicenter, longitudinal follow-up study.
Read More